cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cincor Pharma Inc
3 watching
Current Price
$0
$0.05
(0.19%)
logo-cinc
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,264.79M
52-Week High
52-Week High
43.15
52-Week Low
52-Week Low
10.53
Average Volume
Average Volume
0.15M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,264.79M
icon52-Week High43.15
icon52-Week Low10.53
iconAverage Volume0.15M
iconDividend Yield--
iconP/E Ratio--
What does the Cincor Pharma Inc do?
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Read More
How much money does Cincor Pharma Inc make?
News & Events about Cincor Pharma Inc.
Globe Newswire
2days ago
NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CinCor Pharma, Inc. (NASDAQ: CINC)s sale to ...
PR Newswire
3days ago
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - LBC, ALBO, CINC, LMST STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - LBC, ALBO, CINC, LMST PR Newswire NEW YORK, Jan. 27, 2023 NEW YORK, Jan. 27, 2023 /PRNewswire...
Globe Newswire
5days ago
NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased ...
Business Wire
7days ago
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of CinCor Pharma, Inc. (NasdaqGM: CINC) to AstraZeneca. Under the terms of the proposed transaction, shareholders of CinCor will receive...
PR Newswire
8days ago
Moore Kuehn Encourages GMGI, CINC, ALBO, and PAYA Investors to Contact Law Firm Moore Kuehn Encourages GMGI, CINC, ALBO, and PAYA Investors to Contact Law Firm PR Newswire NEW YORK, Jan. 22, 2023 NEW YORK, Jan. 22, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation...
Frequently Asked Questions
Frequently Asked Questions
What is Cincor Pharma Inc share price today?
plus_minus_icon
Can Indians buy Cincor Pharma Inc shares?
plus_minus_icon
How can I buy Cincor Pharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Cincor Pharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cincor Pharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Cincor Pharma Inc?
plus_minus_icon
What is today’s market capitalisation of Cincor Pharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cincor Pharma Inc?
plus_minus_icon
What percentage is Cincor Pharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cincor Pharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.05
(0.19%)
logo-cinc
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00